[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370359-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370359-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","thsd7a-as-a-novel-prognostic-factor-for-colorectal-carcinoma","THSD7A as a novel prognostic factor for colorectal carcinoma","","Investigation of THSD7A expression as an angiogenesis-related biomarker in colorectal cancer (CRC) was conducted to clarify its prognostic value. Ninety-five CRC patients were grouped by immunohistochemistry status: negative (no staining) versus positive (expression ≥1% of cancer cells). Overall survival was analyzed using Kaplan–Meier estimates and assessed with univariable and multivariable Cox regression models. THSD7A loss correlated with inferior survival and remained an independent predictor together with poor differentiation and advanced stage.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/thsd7a-as-a-novel-prognostic-factor-for-colorectal-carcinoma/370359/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/thsd7a-as-a-novel-prognostic-factor-for-colorectal-carcinoma/370359.png","ImageObject",300,407,{"name":42,"@type":43},"Riley","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-25","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How was THSD7A expression assessed in the study?","Question",{"text":63,"@type":64},"THSD7A expression was determined by immunohistochemistry and classified as negative (no staining) or positive (expression ≥1% of cancer cells).","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What did the study find about overall survival and THSD7A?",{"text":68,"@type":64},"Patients lacking THSD7A expression had inferior overall survival compared with patients with THSD7A expression.",{"name":70,"@type":61,"acceptedAnswer":71},"Which factors were independent predictors of overall survival in multivariable analysis?",{"text":72,"@type":64},"Independent predictors included poor tumor differentiation, advanced stage, and loss of THSD7A expression.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370359,1790638125,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":117,"preview_page_count":33,"preview_urls":144},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","Aktepe etal. BMCGastroenterology (2025) 25:179  \n[https://doi.org/10.1186/s12876-025-03775-5](https://doi.org/10.1186/s12876-025-03775-5)  \nBMC Gastroenterology  \nRESEARCH Open Access  \nTHSD7A as a novel prognostic factor for colorectal carcinoma  \nOktay Halit Aktepe 1*, Olcay Kurtulan2, Pinar Ezgi Dama 1, Ahmet Mel ih Arslan 1, Elif Atag 1, Meral Uner2, Berfu Korucu3, Aziz Karaoglu 1 and Suayib Yalcin4  \nAbstract  \nBackground Thrombospondin type 1 domain-containing 7 A (THSD7A) expression, an angiogenesis-related protein, has been implicated in various aspects of cancer progression, reflecting its potential as a prognostic marker for various cancers. Therefore, we investigated the prognostic value of THSD7A expression in colorectal cancer (CRC) .  \nMethods A total of 95 patients with CRC were included. The patients were stratified into two groups according toTHSD7A expression status determined by immunohistochemistry [negative (no staining), and positive (expression ≥ 1% of cancer cells)] . The overall survival (OS) of prognostic subgroups was estimated by Kaplan Meier method. The prognostic value of THSD7A expression was evaluated by univariable and multivariable Cox regression models.  \nResults THSD7A was expressed in 42. 1% of CRC patients. Patients with noTHSD7A expression had inferior OS than patients with THSD7A expression (72 .9 months vs. median OS was not reached, p = 0 . 001, respectively) . Our multivariate analyses revealed that the independent predictors of OS were poor differentiation of tumor (HR: 2 . 603, p = 0 . 002), advanced stage (HR: 3 . 210, p \u003C 0. 001), and the loss ofTHSD7A expression (HR: 3 . 094, p = 0 . 001) . Conclusions The present study showed that THSD7A expression could serve as a potential prognostic marker for CRC cancer. Further research is warranted to elucidate the exact underlying THSD7A-mediated cancer progression and to explore its clinical use in improving CRC prognostication and treatment strategies.  \nKeywords Colorectal cancer, Prognosis, THSD7A  \n*Correspondence:  \nOktay Halit Aktepe  \n[oktayhal it.aktepe@deu.edu.tr](oktayhal it.aktepe@deu.edu.tr)  \n1Department of Medical Oncology, Dokuz Eylül University Cancer Institute, Izmir, Turkey  \n2Department of Pathology, Faculty of Medicine, Hacettepe University, Ankara, Turkey  \n3Department of Nephrology, Faculty of Medicine, Dokuz Eyl ul University, Izmir, Turkey  \n4Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey  \nIntroduction  \nColorectal cancer (CRC) is one of the most prevalent cancers worldwide and the second most common cause of cancer-related deaths in the United States [1]. Increasing efforts in screening and early detection policy and recent advances in local and systemic treatment modalities have led to better survival outcomes in CRC. Approximately 20% of CRC patients have metastatic disease at initial presentation, indicating a poor prognosis [2]. The combination of systemic chemotherapy agents with monoclonal agents such as anti-vascular endothelial growth factor (VEGF) antibody bevacizumab and anti-epidermal growth factor receptor antibodies, panitumumab and  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutor","cbCairHy9khDJcYV","https://ap.wps.com/l/cbCairHy9khDJcYV","pdf",1341024,"English","# Abstract\n# Introduction\n## Colorectal cancer burden and treatment advances\n## Rationale for THSD7A and angiogenesis signaling","[{\"question\":\"How was THSD7A expression assessed in the study?\",\"answer\":\"THSD7A expression was determined by immunohistochemistry and classified as negative (no staining) or positive (expression ≥1% of cancer cells).\"},{\"question\":\"What did the study find about overall survival and THSD7A?\",\"answer\":\"Patients lacking THSD7A expression had inferior overall survival compared with patients with THSD7A expression.\"},{\"question\":\"Which factors were independent predictors of overall survival in multivariable analysis?\",\"answer\":\"Independent predictors included poor tumor differentiation, advanced stage, and loss of THSD7A expression.\"}]","THSD7A as a novel prognostic factor for colorectal carcinoma | PDF",1790188166,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1d3a9d2240de884afc43f552e80c5e33.webp",983,1310,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6907edfff9a3dbe66b750256938e210e.webp",982,1309,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0b8546ad9388ce07a596b1add51bfda1.webp",981,1308,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/efd814109db638b776630e3c1c5cb706.webp",980,1306]